SCHEMBL6234470

SCHEMBL6234470

Nc1cc(Cn2c(=O)c(C3=NS(=O)(=O)c4ccccc4N3)c(O)c3ccccc32)ccn1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.63
HSD17B10 Q99714 1/20 0.63
CYP2C9 P11712 3/20 0.51
NR1I2 O75469 1/20 0.51
KDM4E B2RXH2 4/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
ALDH1A1 P00352 3/20 0.41
RECQL P46063 2/20 0.41
POLB P06746 1/20 0.41
CASP6 P55212 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HIF1A Q16665 1/20 0.34
MAPT P10636 2/20 0.34
RCE1 Q9Y256 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
EGLN1 Q9GZT9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6738676 0.90 MAPK1 (0.66) MAPK1HSD17B10CYP2C9NR1I2KDM4E
SCHEMBL6233389 0.87 MAPK1 (0.69) MAPK1HSD17B10CYP2C9NR1I2KDM4E
SCHEMBL6231912 0.87 MAPK1 (0.64) MAPK1HSD17B10CYP2C9NR1I2KDM4E
SCHEMBL6235315 0.84 MAPK1 (0.65) MAPK1HSD17B10CYP2C9NR1I2KDM4E
SCHEMBL6237190 0.84 MAPK1 (0.67) MAPK1HSD17B10CYP2C9NR1I2KDM4E
SCHEMBL6738199 0.83 MAPK1 (0.66) MAPK1HSD17B10CYP2C9NR1I2KDM4E
SCHEMBL6884605 0.83 MAPK1 (0.68) MAPK1HSD17B10CYP2C9NR1I2KDM4E
SCHEMBL6733839 0.83 MAPK1 (0.68) MAPK1HSD17B10CYP2C9NR1I2KDM4E
SCHEMBL6241049 0.81 MAPK1 (0.69) MAPK1HSD17B10CYP2C9NR1I2KDM4E
SCHEMBL6235955 0.81 MAPK1 (0.61) MAPK1HSD17B10CYP2C9NR1I2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401443-A4 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORP (US) 2005-10-26 EP claimed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US claimed
EP-1401443-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-03-31 EP claimed
WO-2002098424-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2002-12-12 WO claimed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147739-A1 Novel anti-infectives RPL5, RPL7, RPL35 MAPK1 3699/4885HSD17B10 1428/4885CYP2C9 1218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.